These two show up together constantly in pet-owner searches, almost always paired as a set. They're mechanistically different compounds, and the evidence picture for each looks different once you break it down by species.
Notice a theme? A lot of the momentum behind animal-peptide interest is spilling over from human research. If that side of the story is what actually brought you here, PeptideReport.ai is our sister site covering peptide research for people — register there and get The Peptide Bridge audiobook free, a $29.99 value, delivered to your inbox right away.
Visit PeptideReport.ai + get the free book →| BPC-157 | TB-500 | |
|---|---|---|
| What it is | A synthetic peptide fragment derived from a protein found in gastric juice | A synthetic version of a fragment of thymosin beta-4, a naturally occurring protein |
| Dog-specific data | A published pharmacokinetics study exists in beagles (absorption/metabolism, not an efficacy trial) — see our dogs page | No comparable species-specific pharmacokinetic study identified in the available literature |
| Cat-specific data | No feline-specific studies identified | No feline-specific studies identified |
| Horse-specific data | No equine-specific studies identified | No equine-specific studies identified |
| Why they get paired | Both are marketed under the same broad "recovery and healing" framing and frequently sold or discussed together, which is a marketing pattern, not evidence that they function the same way. | |
BPC-157 and TB-500 are structurally unrelated compounds with different proposed mechanisms — grouping them as an interchangeable pair, or assuming evidence for one applies to the other, isn't supported by anything about how they're described mechanistically. Being sold or discussed as a set is a marketing convention, not a scientific equivalence.
As the table above shows, even the single most concrete data point in this comparison — the beagle pharmacokinetics study for BPC-157 — is dog-specific and doesn't tell you anything about cats or horses, let alone about TB-500. Extending "there's a dog study for BPC-157" into "these are researched for pets" glosses over both the species gap and the compound gap. See our guide to reading the research for more on why this kind of extrapolation is so common in this space.
For the full compound-by-compound picture, see the research index. For species-specific context, see dogs, cats, or horses.
Understanding the research is step one. The real next step is a conversation with a licensed veterinarian who can tell you where your pet's situation actually falls within it.
Talking to Your VetFree bonus: register on PeptideReport.ai today and The Peptide Bridge audiobook — a $29.99 value — is yours free, delivered to your inbox right away.